Patients should be referred to endocrinology for CAH treatment in order to prevent the development of adrenal neoplasia, particularly myelolipoma secondary to increased adrenocorticotropic hormone (ACTH) [3,4]. This evidence concerns the gene POMC and congenital adrenal hyperplasia.